方盛製藥(603998.SH):上半年公司製藥板塊業績持續增長
格隆匯8月7日丨有投資者向方盛製藥(603998.SH)提問:今年上半年“338工程”中的產品表現如何?
方盛製藥回覆:2023上半年公司製藥板塊業績持續增長,強力枇杷膏(蜜煉)、強力枇杷露、賴氨酸維B12顆粒、蒲地藍消炎片以及參芪鹿茸口服液銷售收入均同比增長50%以上;骨骼肌肉系統疾病用藥藤黃健骨片,從2月開始實現銷售收入正增長,但因中成藥集採因素影響,5-6月增幅有所放緩,但上半年銷售收入較上年同期基本持平;國家談判品種玄七健骨片自2月開始銷售,3月1日正式納入國家醫保目錄後,已新增覆蓋456家公立醫療機構,玄七健骨片報吿期內實現銷售收入近千萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.